Status:
COMPLETED
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different dev...
Eligibility Criteria
Inclusion
- Healthy males or non-pregnant females as determined by medical history, physical examination, and other screening procedures
- Body mass index (BMI) between 18.5 and 32.0 kilograms per meter squared (kg/m²), inclusive
- Have clinical laboratory test results, blood pressure and pulse rate that are acceptable for the study
- Are agreeable to receiving study treatment by injections under the skin
- Males who agree to use highly effective/effective methods of contraception and women not of childbearing potential (postmenopausal or oophorectomized)
Exclusion
- Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
- Smoke more than the equivalent of 10 cigarettes per day
- Is a known user of drugs of abuse
- Have known allergies to LY3437943 or related compounds
Key Trial Info
Start Date :
August 29 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 8 2024
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT06003465
Start Date
August 29 2023
End Date
February 8 2024
Last Update
March 29 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Qps-Mra, Llc
Miami, Florida, United States, 33143-4875
2
ICON Early Phase Services
San Antonio, Texas, United States, 78209
3
ICON
Salt Lake City, Utah, United States, 84124